Pelthos Therapeutics Inc.
PTHSNYSE
$26.99
↑ +1.0%Jul 17 close · end-of-day
Price
1Y↑ +33.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$89.4M
Enterprise Value
$57.4M
P/E
—
P/S
—
P/B
2.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$51.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-147.0%
ROIC
-1104.0%
Debt / Equity
—
Net Cash
$32.0M
Return 1Y
+22.0%
Company profile
We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Chromocell Therapeutics Corporation was incorporated in Delaware on March 19, 2021. Our principal executive offices are located at 4400 Route 9 South, Suite 1000, Freehold, NJ.
- CEO
- Francis Knuettel II
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- New Jersey
- Website
- chromocell.com
Management & directors
- Francis Knuettel IiChief Financial Officer
- Plesha Scott M.CEO and President
- Rangarao SaiChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
PTHS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.9M—
Diluted EPS-$3.09↓ -3.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $16.8M |
| Gross profit | — | — | — | — |
| Operating income | -$2.3M | -$6.9M | -$7.6M | -$32.4M |
| Net income | -$2.5M | -$7.4M | -$8.0M | -$43.3M |
| Diluted EPS | — | -$5.78 | -$14.27 | -$23.04 |
| Operating cash flow | -$1.6M | -$981,031.00 | -$5.8M | -$22.6M |
| Free cash flow | — | — | -$5.8M | -$22.7M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | -193.1% |
| Net margin | — | — | — | -257.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | $7.4M | — | $10.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.8M | -$2.0M | -$1.8M | -$1.8M | -$3.2M | -$15.4M | -$12.0M | -$13.1M |
| Net income | -$1.8M | -$1.7M | -$1.9M | -$2.0M | -$3.4M | -$16.2M | -$21.7M | -$10.2M |
| Diluted EPS | -$3.07 | -$2.93 | -$7.72 | -$3.21 | -$5.38 | -$5.30 | -$9.15 | -$3.09 |
| Operating cash flow | -$3.0M | -$177,692.00 | -$670,000.00 | -$632,000.00 | -$447,271.00 | -$15.3M | -$6.3M | -$13.1M |
| Free cash flow | — | — | — | -$632,000.00 | — | — | — | -$13.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -207.4% | — | -120.0% |
| Net margin | — | — | — | — | — | -219.3% | — | -93.9% |
Company news
May 28, 2026
May 14, 2026
- 66d agoPelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...finance.yahoo.com
- 67d agoPelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimatesfinance.yahoo.com
- 67d agoPelthos Therapeutics Announces First Quarter 2026 Financial Resultsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Greenleaf Peter | Sale | 712 | $26.00 | $18,508.72 | filing |
| 2026-07-02 | Pauls Matthew | Sale | 692 | $26.00 | $17,989.16 | filing |
| 2026-07-02 | Friedberg Ezra M | Sale | 534 | $26.03 | $13,900.18 | filing |
| 2026-07-02 | Pauls Matthew | Sale | 94 | $27.36 | $2,571.88 | filing |
| 2026-07-02 | Greenleaf Peter | Sale | 85 | $27.27 | $2,318.23 | filing |
| 2026-07-02 | Friedberg Ezra M | Sale | 24 | $27.33 | $655.81 | filing |
| 2026-06-15 | Friedberg Ezra M | Sale | 224 | $27.12 | $6,075.89 | filing |
| 2026-06-15 | Friedberg Ezra M | Sale | 59 | $27.94 | $1,648.48 | filing |
| 2026-06-11 | Davis Todd C | Buy | 35,445 | $27.80 | $985,534.05 | filing |
| 2026-06-11 | Davis Todd C | Buy | 503 | $28.73 | $14,449.23 | filing |
| 2026-05-22 | Francis Knuettel II· CFO, Treas & Secty | Sale | 1,500 | $26.84 | $40,264.95 | filing |
| 2026-05-22 | Francis Knuettel II· CFO, Treas & Secty | D | 13,947 | $0.00 | $0.00 | filing |
| 2026-05-14 | Friedberg Ezra M | Tax withholding | 144 | $27.01 | $3,889.01 | filing |
| 2026-04-02 | Greenleaf Peter | Sale | 420 | $20.52 | $8,616.34 | filing |
| 2026-04-02 | Pauls Matthew | Sale | 415 | $20.52 | $8,513.89 | filing |
| 2026-04-02 | Greenleaf Peter | Sale | 377 | $21.36 | $8,053.25 | filing |
| 2026-04-02 | Pauls Matthew | Sale | 371 | $21.36 | $7,925.60 | filing |
| 2026-04-02 | Malamut Richard | Sale | 310 | $20.51 | $6,358.91 | filing |
| 2026-04-02 | Friedberg Ezra M | Sale | 293 | $20.51 | $6,010.05 | filing |
| 2026-04-02 | Malamut Richard | Sale | 280 | $21.36 | $5,981.14 | filing |
| 2026-04-02 | Friedberg Ezra M | Sale | 265 | $21.36 | $5,660.72 | filing |
| 2025-12-23 | Einhorn Andrew J. | Award | 12,000 | — | — | filing |
| 2025-12-10 | Pauls Matthew | Gift | 9,542 | $0.00 | $0.00 | filing |
| 2025-11-25 | Friedberg Ezra M | Sale | 5,999 | $28.00 | $167,972.00 | filing |
| 2025-11-25 | Friedberg Ezra M | Sale | 2,000 | $28.14 | $56,270.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.